Article
Crystal structure and molecular dynamics simulations of rademikibart Fab-IL-4Rα complex reveal biochemical basis for next-generation potent IL-4Rα inhibition in type 2 allergic and inflammatory diseases
2026-04-13
Abstract excerpt
Rademikibart (CBP-201) is a human monoclonal antibody with higher binding affinity to IL-4Rα compared to dupilumab. Dupilumab is a first-generation interleukin-4 receptor alpha (IL-4Rα) inhibitor for treating IL-4Rα-dependent inflammatory disorders, including several dermatologic and respiratory conditions. Rademikibart, however, demonstrated better inhibition of STAT6 intracellular signaling in vitro and similar...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 9a62e90e-57eb-56cc-99ea-5534ac37ffec
- DOI
- 10.64898/2026.04.12.718052
